Latent Tuberculosis Infection and Biological Therapy

Czech version

Authors: I. Solovič ¹; Z. Klimentová ²
Authors‘ workplace: Fakulta zdravotníctva Katolíckej univerzity, Ružomberok, NUTPCHaHCH Vyšné Hágy ¹; Klinika pneumológie a ftizeológie SZU Bratislava ²
Published in: Čes-slov Derm, 90, 2015, No. 3, p. 112-118
Category: Pharmacologyand Therapy, Clinical Trials

Overview

Latent (subclinical) tuberculosis infection means tuberculosis mycobacteria harbor in the organism, but do not cause disease. Only about 10–15% of latently infected persons actually become ill with active tuberculosis. The transition to active disease is influenced by circumstances which weaken the immune system, especially the cellular immunity. This problem took on added importance today, when the number of patients treated with biological drugs increases. These patients are extremely susceptible to tuberculous disease. Latent tuberculosis infection is not diagnosed by conventional diagnostic methods. In the past only the tuberculin skin test was used for diagnosis. Currently we have two available immunoassays – IGRA (Interferon Gamma Release Assay) with higher sensitivity and specificity able to rule out false positives due to BCG vaccination, which may occur in the tuberculin skin test.

Keywords:
latent tuberculosis infection – biological therapy – IGRA tests

Sources

1. FERRARA, G., LOSI, M., MEACCI, M. Routine Hospital Use of a New Commercial Whole Blood Interferon γ Assay for the Diagnosis of Tuberculosis Infection. Am. J. resp. crit. Care Med., 172, 2005, 1, p. 631–635.

2. JENSEN, P. A., LAMBERT, L. A., IADEMARCO, M. F., RIDZON, R.: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm. Rep., 2005, 54, s. 1–141.

3. KIMBAL, A. B. et al.: Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension. Br. J. Dermatol., 2012; 167 (suppl.1), p. 63–64.

4. LEONARDI, C. L., KIMBALL, A. B., PAPP, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, p. 1665–1674.

5. MACK, U., MIGLIORI, G. B., SESTER, M. et al. LTBI – latent tuberculosis infection or lasting immune response to M. tuberculosis? A TB NET consensus statement. Eur. Respir. J., 33, 2009, 5, p. 956–973.

6. MAZUREK, G. H., JEREB, J., LOBUE, P. et al. Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection,United States. MMWR Recomm. Rep., 2005, 54, p. 49–55.

7. PAPP, K. A., LANGLEY, R. G., LEBWOHL, M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371, p. 1675–16.84

8. ROZBORILOVÁ, E., SOLOVIČ, I., CHOVAN, L. Metodické odporúčanie hlavného odborníka na vyšetrovanie Quantiferon TB Goldtestu u pacientov liečených biologickou liečbou. 2007, s. 10. (http://spfs.cme.sk/sz/content/545-31816/metodicke-odporucanie-hlavneho-odbornika-mz-sr-pre-odbor-pneumologia-a-ftizeologia-na-vysetrovanie-q.html).

9. SCOTT, D. L., KINGSLEY, G. H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med., 2006, Aug 17, 355 (7), p. 704–712.

10. SOLOVIČ, I.: Nová diagnostická metóda na vyšetrenie latentnej ako aj aktívnej tuberkulóznej infekcie: Interferon γ release assay – IGRA. Stud. Pneumol. Phtiseol., 2006, 66, s. 221–222.

11. SOLOVIČ, I. Spoločné vyhlásenie TBNET – Riziko vzniku tuberkulózy pri liečbe TNF antagonistami. Stud. Pneumol. Phtiseol., 71, 2011, 1, s. 15–21.

12. SOLOVIČ, I., SESTER, M., GOMEZ-REINO, J. J. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur. Respir. J., 2010, 36, s. 1185–1206.

13. TSAI, T. F., HO, V., SONG, M. et. al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br. J. Dermatol., 2012, Nov;167 (5), p. 1145–1152.

14. TRNKA, L., WALLENFELS, J. Latentní tuberkulózní infekce, její význam v kontrole tuberkulózy v zemích s hromadnou BCG vakciinací. Stud. Pneumol. Phtiseol., 2006, 66, s.196–202.

15. UK National Institute for Health and Clinical Excellence (NICE) Tuberculosis. Clinical diagnosis and management of tuberculosis and measures for its prevention and control. Clinical Guideline, 33, 2006, s. 51 (www.nice.org.uk/CG033).

16. WHO Guidelines on the management of latent tuberculosis infection. ISBN: 978 92 4 154890 WHO reference number: WHO/HTM/TB/2015.01, 2014, s. 38.

Labels

Dermatology & STDs Paediatric dermatology & STDs

Agminated Histiocytomas

Fibroepithelioma Pinkus

Erythema of the Glans Penis

Neurofibromatosis from the View of Dermatologist

Article was published in

Czech-Slovak Dermatology

2015 Issue 3